TALPHERA Business Summary

Talphera, Inc. (formerly AcelRx Pharmaceuticals) is a clinical-stage specialty pharmaceutical company that generates revenue primarily through strategic licensing agreements, private placement financing, and the anticipated commercialization of its lead product candidates. The company’s business model is centered on developing and commercializing innovative therapies for medically supervised settings, with primary segments focused on regional anticoagulants and pre-filled syringe (PFS) technologies. Its flagship candidate, Niyad, is a lyophilized formulation of nafamostat currently in the NEPHRO pivotal study for use as a regional anticoagulant in continuous renal replacement therapy (CRRT). Talphera competes directly with biopharmaceutical firms such as Milestone Pharmaceuticals, Rani Therapeutics, ProQR Therapeutics, and Caribou Biosciences. Within this landscape, Talphera occupies a specialized niche by targeting the high-unmet-need hospital market for extracorporeal circuit anticoagulation, positioning itself as a provider of safer alternatives to systemic heparin. The leadership team is led by Chief Executive Officer Vincent J. Angotti, who brings over three decades of pharmaceutical experience from roles at XenoPort and Reliant Pharmaceuticals. The company was co-founded by Dr. Pamela P. Palmer, who serves as Chief Medical Officer and previously directed the UCSF Pain Management Center. Other key executives include Chief Financial Officer Raffi Asadorian, formerly of Amyris and Barr Pharmaceuticals, and Chief Engineering Officer Badri Dasu, who oversees technical operations and product development. Dr. Shakil Aslam serves as the Chief Medical Officer leading the clinical development of the Niyad program. Notable board members include Independent Chairman Adrian Adams and Joseph Todisco, the CEO of CorMedix Inc., which recently became a strategic investor. Major institutional backing is provided by CorMedix and Rosalind Advisors, reflecting a strategic focus on securing the regulatory pathway for Niyad through 2026.